Abstract. As a new strategy, radio-gene therapy was widely used for the treatment of cancer patients in recent few years. Slug was involved in the radioresistance of various cancers and has been found to have an anti-apoptotic effect. This study aims to investigate whether the modulation of Slug expression by siRNA affects oral squamous cell carcinoma sensitivity to X-ray irradiation through upregulating PUMA. Two oral squamous cell carcinoma cell lines (HSC3 and HSC6) were transfected with small interfering RNA (siRNA) targeting Slug and subjected to radiotherapy in vitro. After transfection with Slug siRNA, both HSC3 and HSC6 cells showed relatively lower expression of Slug and higher expression of PUMA. The Slug siRNA transfected cells showed decreased survival and proliferation rates, an increased apoptosis rate and enhanced radiosensitivity to X-ray irradiation. Our results revealed that Slug siRNA transfection in combination with radiation increased the expression of PUMA, which contributed to radiosensitivity of oral squamous cell carcinoma cells. Thus, controlling the expression of Slug might contribute to enhance sensitivity of HSC3 and HSC6 cells toward X-ray irradiation in vitro by upregulating PUMA.

Introduction

Radio-gene therapy, which combined traditional radiotherapy with gene therapy, was developed rapidly in recent few years as a new strategy (1-3). It has the advantage of reducing X-ray irradiation dose while enhancing the efficacy of gene therapy. As the standard adjuvant treatment, radiotherapy has played an important role in controlling tumor growth, however, it may be sometimes ineffective and resulting in unnecessarily severe side effects due to a significant proportion of radiation resistance (4-7). As for gene therapy, one of the most pivotal reasons that restricts the clinical applications of it in treating tumors is poor target activity. Therefore, for successful prediction of radiotherapy resistance, it is crucial to find a radiosensitive tumor target and to understand the mechanisms underlying the development of radioresistance in tumors.

Slug (Snail 2), which belongs to the Snail family, is a highly evolutionarily conserved zinc-finger transcription factor. It presents an anti-apoptotic effect by regulation of the transactivation of PUMA, Bcl-2 and Bax expression (8,9). The members of the Slug/Snail superfamily share a similar zinc finger domain and the same Snag domain (10). Slug-deficient cells were radiosensitive to DNA damage and the function of Slug in response to DNA damage seemed to be important for its function in both normal development and cancer (11,12).

P53 upregulated modulator of apoptosis (PUMA), which has a powerful pro-apoptotic effect, is a key protein in apoptosis and might be a potential new target for radio-gene therapy (13-15). It has been reported that PUMA could increase sensitivity to radiation-induced apoptosis in certain kinds of tumor cells both in vivo and in vitro (15-19). As a suppressor of PUMA transcription, Slug plays an important role in the tumorigenesis and development of resistance to radiation therapy by suppressing the expression of PUMA (15,20,21). Zhang et al found that in cholangiocarcinomas Slug might be a potential target as an inducer of PUMA and Slug inhibition could upregulate radiation-induced PUMA activity leading to cell apoptosis (15).

Although the role of Slug in cancer progression has been well understood, Slug inhibition induced alteration in radiosensitivity of OSCC cells has not been analysed. Thus, the aim of this study was to explore whether Slug inhibition could increase radiosensitivity of oral squamous cell carcinoma HSC3 and HSC6 cells by upregulating PUMA. The results indicated that after the combined treatment of Slug siRNA transfection and X-ray irradiation, the expression of Slug was reduced and PUMA expression was upregulated, resulting in increased cell apoptosis. These findings offer new insight into the relationship of Slug and PUMA in OSCC cells and provide a new kind of radio-gene therapy of OSCC.
Materials and methods

Patients and tissue acquisition. Surgically resected OSCC specimens were obtained from 57 OSCC patients between September 2008 and April 2013 in the Stomatology of Sun Yat-sen University with written informed consents as a prospective study. All cases were divided into phase I to IV according to the UICC (Union for International Cancer Control) standard in 2002 and the experimental procedures were approved by the Research Ethics Committee of Sun Yat-sen University. A summary of the characteristics in the 57 OSCC cases are presented in Table I. In addition, 15 cases of normal tissue were collected as control.

Immunohistochemical staining. Immunohistochemistry was used to detect the expression of Slug and PUMA in OSCC specimens. Ten percent formalin-fixed and paraffin-embedded samples were cut into 4-µm thick sections. The sections were deparaffinized using xylene and rehydrated through an increased grades of ethanol. After antigen retrieval, primary rabbit polyclonal antibodies to Slug and PUMA both at 1:200 dilution were added for treatment at 4˚C overnight. Then immunohistochemical staining was performed according to the recommended protocol. Sections were considered either as positive or negative according to the presence or absence of brown staining in OSCC epithelial or stromal cells.

Cell culture. The human oral squamous cell carcinoma cell lines HSC3 and HSC6 were obtained from the American Type Culture Collection and conserved in Guangdong Provincial Key Laboratory of Stomatology of Sun Yat-sen University. Cells were cultured in DMEM supplemented with fetal calf serum (10%) in a humidified 5% CO2 incubator at 37˚C. Cells were used in the exponential growth phase in all experiments.

Slug siRNA transfections. A validated negative universal control was used as a control for transfection. Three different strand Slug-targeting siRNA oligonucleotides were used together and the siRNA oligonucleotide that showed the highest knockdown efficiency of Slug mRNA in HSC3 and HSC6 cell lines was used for the experiments. The transfections were carried out using Lipofectamine™RNAi MAX according to the recommended protocol.

Radiation treatment and clonogenic survival assay. Irradiation was performed in a linear accelerator (RS2000, Hong Kong) at a dose rate of 1.31 Gy/min at room temperature. HSC3 and HSC6 cells were irradiated with five single-radiation doses (0, 2, 4, 6 and 8 Gy) using X-ray-irradiation equipment and then returned to the incubator. Twenty-four hours after irradiation, cells were trypsinized and plated in 60-mm dishes and incubated for 12-14 days to allow colony growth to assay their colony-forming ability. The colonies were stained with crystal violet and colonies containing ≥50 cells were counted. Each experiment was repeated three times and the survival curves were plotted by GraphPad Prism 3.0 software program. For the treatment combination of Slug siRNA transfection and radiation, cells were first transfected with Slug siRNA, and then irradiated with 4 Gy X-ray according to previous description 24 h later. Both HSC3 and HSC6 cells were divided into five groups, including control group, scramble group, Slug siRNA group, radiation group and Slug siRNA combination with radiation group which were used for further analysis.

RNA isolation and real-time qRT-PCR. Total RNA was isolated from HSC3 and HSC6 cell lines in all treatment conditions using TRIzol reagent according to the manufacturer's instructions. Real-time qRT-PCR analysis was performed to validate mRNA expression with the one-step RT-PCR kit and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. The nucleotide sequences of specific primers for mRNA amplification were designed using Beacon Designer Software and its sequences were as follows: the sequence of Slug: sense, CTTGCCAACGAGCAAGG; antisense, GTTTGCAGCAGCACGAGC; the sequence of PUMA: sense, CCAGGAAAGGCTGTGTTGCTG; antisense, TCACTCGGTTTGACTGGTG; the sequence of GAPDH: sense, TGATGAGGTGAGAACCAGAG; antisense, TGGAAGTCGGAGGACAAACC. The RT-PCR conditions were as follows: 95˚C for 5 min, followed by 40 cycles of 95˚C for 15 sec, 60˚C for 15 sec and 72˚C for 1 min and the final extension was 72˚C for 5 min. Relative gene expression levels were calculated using the 2-ΔΔCt method.

Western blot analysis. Western blot analysis was used to investigate the expression of Slug and PUMA protein according to the manufacturer's protocol. Cells in different groups were lysed in protein lysis buffer supplemented with 1 mM of PMSF (phenylmethylsulfonyl fluoride) and protease inhibitor mixture. Protein concentration was measured by BCA protein assay kit and then diluted with 5X loading buffer and denatured for 10 min at 99˚C. Thirty grams of protein per lane in all treatment conditions were separated on 12% SDS-PAGE and subsequently transferred to a PVDF (polyvinylidene difluoride) membrane by electro-blotting. The membranes were blocked with 5% non-fat dry milk and incubated with the primary antibodies against Slug, PUMA, Caspase-3, Bax, Bcl-2 and GAPDH (1:1,000 dilution) at 4˚C for 6 h. Then the membranes were washed with TBST and incubated with the secondary antibody for 1.5 h at room temperature. Membranes were detected according to an ECL (enhanced chemiluminescence) reagent kit instruction and visualized in the AlphaView SA system. Quantity One software was used for analysis.

Immunofluorescence. HSC3 and HSC6 cells were seeded in laser-scanning confocal Petri dishes and incubated at 37˚C overnight. Firstly, after different treatments for 48 h, cells were washed with PBS for three times and fixed in 4% paraformaldehyde for 20 min and then permeabilized with 1% Triton X-100 for 30 min and sequentially blocked in 1% BSA for 20 min. Secondly, the treated cells were incubated with primary antibodies (Slug and PUMA) according to manufacturer’s protocols for 18 h and then incubated with the corresponding secondary antibody for 1 h. Lastly, DAPI (4',6-diamidino-2-phenylindole) was used to stain nuclei. Images were captured by confocal laser scanning microscopy.

Cell viability assay. HSC3 and HSC6 cells were seeded into 96-well plates at 4,000 cells/well. After treatment as described above, 20 μl MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2-H-tetrazolium bromide, 5 µg/µl) was added per well and incubated for 4 h at 37˚C in a humidified environment at 24, 48, 72, 96 and 120 h post-transfection. The supernatant was discarded and 200 µl DMSo (dimethyl sulphoxide) was added to each well to dissolve the precipitate. Optical density (oD) value was measured at the wavelength of 570 nm. Each test was repeated in eight wells and performed daily for five days.

Cell cycle assay. Cells in different groups were washed twice with PBS, harvested, fixed with 70% ethanol and then stained with propidium iodide (PI, 20 µg/ml) for 30 min at 4˚C. Samples were analyzed by fluorescence-activated cell-sorting (FACS) flow cytometer and the data were elaborated using Modfit software. Each test was repeated in triplicate.

Annexin V staining. The Annexin V staining was performed to measure cell apoptosis according to the manufacturer's protocol. After treatment, HSC3 and HSC6 cells in the log phase of growth were collected and resuspended in binding buffer at a density of 10^6 cells/ml. An Annexin V-FITC labeled Apoptosis Detection kit was used for the apoptosis assay and the percentage of apoptotic cells was quantified by flow cytometry. Each test was repeated in triplicate.

Statistical analysis. All data were performed using the SPSS17.0 software and the results are presented as mean ± SD and determined by one-way analysis of variance (ANOVA) or t-test of three replicate assays. P-value <0.05 was considered to indicate statistical significance.

Results

The expression of Slug and PUMA in OSCC samples. First, the expression of Slug and PUMA were examined by the immunohistochemical staining respectively in human OSCC tissues and normal tissues (Fig. 1). As showed in Table II, Slug

<table>
<thead>
<tr>
<th>Clinicopathological profiles</th>
<th>Slug expression</th>
<th>PUMA expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of tumor specimens (n)</td>
<td>n</td>
<td>χ²</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;60</td>
<td>36</td>
<td>25</td>
</tr>
<tr>
<td>≤60</td>
<td>21</td>
<td>14</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>25</td>
<td>16</td>
</tr>
<tr>
<td>Female</td>
<td>32</td>
<td>23</td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I+II</td>
<td>22</td>
<td>11</td>
</tr>
<tr>
<td>III+IV</td>
<td>35</td>
<td>28</td>
</tr>
<tr>
<td>Differentiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well</td>
<td>15</td>
<td>11</td>
</tr>
<tr>
<td>Moderately</td>
<td>29</td>
<td>16</td>
</tr>
<tr>
<td>Poorly</td>
<td>13</td>
<td>12</td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>37</td>
<td>26</td>
</tr>
<tr>
<td>Positive</td>
<td>20</td>
<td>13</td>
</tr>
<tr>
<td>Total</td>
<td>57</td>
<td>39</td>
</tr>
</tbody>
</table>

Table I. Relations of Slug and PUMA expression with clinicopathological profiles.

Table II. The expression of Slug and PUMA in OSCC tissues and normal tissues.

<table>
<thead>
<tr>
<th>Group</th>
<th>Slug expression</th>
<th>PUMA expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.of tumor specimens (n)</td>
<td>n</td>
<td>χ²</td>
</tr>
<tr>
<td>OSCC tissues</td>
<td>57</td>
<td>39</td>
</tr>
<tr>
<td>Normal tissues</td>
<td>15</td>
<td>4</td>
</tr>
</tbody>
</table>
expression was observed in 68.4% (39/57) of OSCC samples and in 26.7% (4/15) of normal tissues ($\chi^2=8.607$, $P=0.003$). In contrast, PUMA expression exhibited an opposite trend compared with the expression of Slug in OSCC samples (22.8%, 13/57) and normal tissues (66.7%, 10/15) ($\chi^2=10.508$, $P=0.001$). The results showed that the expression of PUMA was significantly higher than Slug in OSCC samples. The relationship between Slug and PUMA expression and clinicopathological profiles was evaluated (Table I). The expression of Slug was significantly lower in early stages (I+II) than in advanced stages (III+IV) ($\chi^2=5.627$, $P=0.018$). In contrast, PUMA expression was higher in early stages than in advanced stages ($\chi^2=6.669$, $P=0.010$). The data showed that Slug and PUMA expression was positively correlated with tumor stage ($P<0.05$) and negatively correlated with patient age, gender, tumor differentiation and lymph node metastases ($P>0.05$), suggesting that they play an important role in the progression of OSCC.

**Slug siRNA transfection inhibits the expression of Slug at both mRNA and protein levels in OSCC cell lines.** We analyzed the effect of Slug siRNA on HSC3 and HSC6 cell lines (Fig. 2). RT-PCR and western blot analysis showed that Slug siRNA transfection resulted in a reduction at Slug mRNA (90-95%) and protein (80-90%) level in both cell lines compared with control or scramble group ("$P<0.01$).
Knockdown of Slug upregulates PUMA expression in OSCC cell lines. PUMA is a common tumor suppressor gene and exhibited a very low expression in OSCC cell lines. In contrast, Slug was highly expressed in many tumors as an oncogene and has been shown to be involved in cell apoptosis by regulation of PUMA. Therefore, we intended to evaluate whether silencing of Slug plays an important role in upregulating PUMA in HSC3 and HSC6 cells. To assess the effect of endogenous Slug on PUMA expression, we transfected Slug siRNA into HSC3 and HSC6 cells and analyzed the expression of PUMA mRNA by RT-PCR and analyzed PUMA protein expression by western blot and immunofluorescence analyses. The data showed that Slug expression was decreased and PUMA was upregulated in Slug sirNA group and no significant change of Slug and PUMA expression was detected in control or scramble group (Fig. 3).

Effect of Slug siRNA transfection on OSCC cell survival and radiosensitivity. To investigate the potential effects of Slug siRNA transfection alone or in combination with X-ray irradiation on HSC3 and HSC6 cell survival, clonogenic survival assay was applied. The results suggested that Slug inhibition could decrease cell proliferation and increase cell sensitivity to X-ray irradiation (Fig. 4). Statistical analysis showed that cell colony forming efficiency (Fig. 4B and E) and survival rate (Fig. 4C and F) were gradually decreased with the increasing radiation dose in control group (P<0.01), scramble group (P<0.01) and Slug siRNA group (P<0.01) of HSC3 and HSC6 cells. Compared with the other two groups, cell colony forming efficiency and survival rate in Slug siRNA radiation group was significantly reduced at the same radiation dose (P<0.05) and there was no significant difference between control group and scramble group (P>0.05). A dose of 4-Gy was selected for subsequent experiments according to the survival rate (50-70%) of OSCC cells.

Effect of Slug inhibition combined with X-ray irradiation on OSCC cell cycle and cell proliferation. We assessed whether Slug inhibition or/and X-ray irradiation treatment modulated cell cycle progress. Slug siRNA and X-ray irradiation induced a significant increase in the percentage of S phase cells in hSc3 (fig. 5A-c; P<0.05) and hSc6 (fig. 5D-f; P<0.01) cells. To evaluate the synergistic effect of Slug siRNA and X-ray irradiation on cell proliferation, we used CCK8 assay to compare the growth of HSC3 and HSC6 cells when treated with Slug siRNA alone or with radiation. As shown in Fig. 5, HSC3 and HSC6 cells proliferated at a significantly lower rate in Slug siRNA/radiation group than did other groups at day 2 (HSC3 F=4.199, P=0.019; HSC6 F=3.623, P=0.031), day 3 (HSC3 F=4.121, P=0.021; HSC6 F=4.751, P=0.013) and day 4 (HSC3 F=3.464, P=0.036; HSC6 F=3.391, P=0.039) and there was no obvious difference of cells proliferation at day 1 (HSC3 F=2.092, P=0.137; HSC6 F=0.586, P=0.711) and day 5 (HSC3 F=1.888, P=0.170; HSC6 F=1.944, P=0.160). Thus, the results showed that Slug inhibition combined with X-ray irradiation could inhibit cell proliferation through increasing cells in S phase.

Radiation treatment affects the expression of proteins involved in apoptotic processes. To assess the effect of X-ray irradiation
on the expression of Slug and PUMA, we analyzed Slug and PUMA expression at both mRNA and protein levels in HSC3 and HSC6 cells that received 4-Gy X-ray irradiation. Our data showed that the expression of Slug were strikingly higher in radiation group than control group, however, there was no obvious Slug upregulation in Slug siRNA group compared with radiation group. It was indicated that X-ray irradiation could improve Slug expression in HSC3 and HSC6 cells.

Figure 3. Expression of Slug and PUMA both at protein and mRNA levels in Slug siRNA transfected HSC3 (A-D) and HSC6 (E-H) cells. As determined by western blot analysis (A and E) and immunofluorescence (B and F), Slug was inhibited and PUMA exhibited an opposite trend in Slug siRNA group in HSC3 and HSC6 cells. (C and G) Relative expression of Slug and PUMA was quantified after normalization with the density of GAPDH by ImageJ Instrument software. (D and H) RT-PCR analysis was used to detect Slug and PUMA mRNA levels. Values indicated as mean ± SD of three independent experiments. *Statistical significance (P<0.05); and **obvious statistical significance (P<0.01).
As for PUMA, the results showed that PUMA expression increased significantly after X-ray irradiation or Slug siRNA transfection compared with control group. To investigate the effect of Slug siRNA transfection in combination with X-ray irradiation on PUMA activity, we measured PUMA expression after the above treatment in HSC3 and HSC6 cells. RT-PCR and western blot analysis showed that cells treated withSlug siRNA transfection and radiation displayed notable increased PUMA expression when compared with radiation group or Slug siRNA group. The data indicated that both Slug siRNA transfection and radiotherapy could upregulate the expression of PUMA. In addition, Caspase-3 and Bax were observed to be overexpressed in Slug siRNA, radiation, scramble/radiation and Slug siRNA/radiation groups. In contrast, Bcl-2 exhibited an opposite trend (Fig. 6A and B).

**Discussion**

Oral squamous cell carcinoma (OSCC) is the most common type of oral cancer and accounts for >90% of it. Despite advances in the common treatments such as surgery, chemotherapy, radiotherapy or a combination of them for OSCC patients, the overall survival rate has not been drastically improved over the past few years (22-25). Radiotherapy played an important role in the treatment of OSCC, however, its efficacy was still limited mainly due to some patients exhibit tolerance to radiotherapy. Therefore, reducing the radiation tolerance and increasing sensitivity to radiotherapy has become a breakthrough to improve the efficacy of OSCC patients.

Slug is involved in the chemoresistance and radiosensitivity of several types of cancers (26,27). As an E-cadherin repressor
Figure 5. Slug siRNA and X-ray irradiation restrains OSCC cell proliferation. HSC3 (A-C) and HSC6 (D-F) cell cycles were detected by flow cytometry analyses in different groups. CCK8 assay was used to detect the growth of HSC3 (G and H) and HSC6 (I and J) cells treated with Slug siRNA and 4 Gy X-ray irradiation. Every experiment was done at least three times.
and a suppressor of PUMA, and Slug has been proved to play an important role in controlling cell apoptosis recently. Zhang et al (15) found that Slug is a considerable modulator of the therapeutic response of cholangiocarcinoma cells and may be potentially useful as a sensitizer in cholangiocarcinoma therapy. One of the mechanisms is the regulation of PUMA by Slug. Xu et al (8) found that Slug overexpression in CNE-2-RES cells may result in the radioresistance of cells and Slug mediates CNE-2 radioresistance via downregulation of PUMA in both a p53-dependent and p53-independent manner. Some studies (28) confirmed the survival function of Slug-PUMA axis in human breast cancer cells that Slug knockdown increased PUMA expression and inhibited lung colonization and demonstrated a pivotal role for Slug in carcinoma cell survival, which implied that disruption of the Slug-PUMA axis may impinge on the survival of metastatic cells. To assess the effect of endogenous Slug on PUMA expression in HSC3 and HSC6 cells, we transfected Slug siRNA into cells and analyzed the expression of PUMA mRNA and protein expression. In agreement with this notion, our data showed that Slug expression was decreased and PUMA was upregulated in Slug siRNA group which evaluated that silencing of Slug played an important role in upregulating PUMA expression in HSC3 and HSC6 cells.

As a member of the Bcl-2 family, PUMA was discovered in 2001 and identified as an essential mediator of p53-independent and p53-dependent apoptosis (29,30). PUMA was localized in the mitochondria and could kill a variety of human cancer cells by activating caspases through mitochondrial dysfunction (13,31). PUMA also functioned through other Bcl-2 family members, such as Bcl-2, Bcl-XL and Bax (32). Although the specific mechanism for PUMA inducing apoptosis needs...
further investigation, it has been shown to be a promising new target in gene therapy (33,34). The goal of this study was to explore the effect of combining Slug siRNA with X-ray irradiation on HSC3 and HSC6 cells. We found that downregulation of Slug expression was correlated with the sensitivity of OSCC cells to radiotherapy. However, further studies are needed to investigate the mechanism that Slug silencing exerts its anti-survival and pro-apoptotic effect in OSCC cells.

In this study, the inhibition of Slug was efficient in suppression of proliferation and induction of apoptosis in HSC3 and HSC6 cells. Surprisingly, the combination of Slug siRNA and X-ray irradiation induced a relatively higher apoptosis as compared with Slug siRNA or X-ray irradiation alone in OSCC cells. We performed the clonogenic survival assay which demonstrated that the treatment with Slug downregulation and X-ray irradiation synergistically reduced clonogenic survival to address that the induction of apoptosis may lead to long-term response to radiotherapy. The data revealed that Slug downregulation potentially enhanced radiosensitivity of HSC3 and HSC6 cells in vitro by increasing PUMA expression.

In conclusion, this study indicates that Slug may be a potential target as an inducer of PUMA and inhibition of Slug by Slug siRNA may be a strategy to overcome radioresistance by upregulation of PUMA. These findings provided new information for novel combinational therapies using Slug siRNA to cooperate with X-ray irradiation in patients with OSCC.

Acknowledgements

This study was supported by the National Natural Sciences Foundation of China (nos. 81272554 and 81472526), the Guangdong Sciences and Technology Project (no. 2016A020216007).

References


Further detailed references included in the full text document.